Analytical Considerations When Developing an LC-MS/MS Method for More than 30 Analytes

• Published in: The journal of applied laboratory medicine 2018-01, Vol.2 (4), p.543-554
• Main Authors: Enders, Jeffrey R, Smith, Jeremy P, Feng, Sheng, Strickland, Erin C, McIntire, Gregory L
• Format: Article
• Language: English
• ISSN: 2576-9456; 2475-7241; 2475-7241
• DOI: 10.1373/jalm.2017.024174

While validation of analytical (LC-MS/MS) methods has been documented in any number of articles and reference texts, the optimal design and subsequent validation of a method for over 30 analytes presents special challenges. Conventional approaches to calibration curves, controls, and run time are not tenable in such methods. This report details the practical aspects of designing and implementing such a method in accordance with College of American Pathologists validation criteria. Conventional criteria were followed in the design and validation of a method for 34 analytes and 15 internal standards by LC-MS/MS. These criteria are laid out in a standard operating procedure, which is followed without exception and is consistent with College of American Pathologists criteria. The method presented herein provides quality results and accurate medication monitoring. The method was optimized to negate interferences (both from within the method and from potential concomitant compounds), increase throughput, and provide reproducible quality quantification over relevant analyte concentrations ranges. The method was designed primarily with quality and accurate medication monitoring in mind. The method achieves these goals by use of novel approaches to calibration curves and controls that both improve performance and minimize risk (financial and operational). As automation and LC-MS/MS equipment continue to improve, it is expected that more methods like this one will be developed.